Pirfenidone to Treat Kidney Disease in Diabetics
Research is undergoing to determine whether the experimental drug pirfenidone can slow kidney disease in diabetics. The study is recruiting patients. Pirfenidone has been beneficial in other diseases involving scar formation, such as pulmonary fibrosis and focal segmental glomerulosclerosis. The drug may be able to slow scar formation in diabetic kidney disease as well, possibly prolonging kidney function.
Patients 18 years of age and older with type 1 or 2 diabetes who have increased protein leakage in their urine (proteinurea), whose blood pressure and blood sugar are well controlled, and who are taking ACE inhibitors or angiotensin receptor blockers may be eligible for this study.
This study is conducted at the NIH Clinical Center in Bethesda, Maryland, and at Thomas Jefferson University in Philadelphia, Pennsylvania.
The study will also check if perfenidone can deliver benefits in diabetic eye problems. via
